HIV/AIDS

For more than 25 years, Merck has been at the forefront of the global response to the HIV/AIDS epidemic.

Merck scientists were among the first to discover and develop medicines for HIV. Merck has introduced four ARVs: ATRIPLA® (efavirenz), CRIXIVAN® (indinavir sulfate), STOCRIN® (efavirenz), and ISENTRESS® (raltegravir) and has worked to expand access to these medicines, particularly for patients in countries that are poorest and hardest hit by the epidemic today. We continue our efforts to address the impact of the disease in resource-limited settings.

Topics covered in this section include:


  • Copyright © 2009-2011 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
TRUSTe - Click to Verify    This Web This Web Accessibility icon serves as a link to download eSSENTIAL Accessibility assistive technology software for individuals with physical disabilities. It is being featured as part of a Disability Community Involvement initiative that reflects our commitment to Diversity, Inclusion,Corporate Citizenship and Social Responsibility.